Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals(ARMP) Prnewswire·2024-11-13 21:05LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2024, and provided a corporate update.Third Quarter 2024 and Recent Developments: Completed enrollment of the Phase 2 study ("Tailwind") of inhaled A ...